Regeneron Says Its Antibody Cocktail Reduces The Risk of Covid By More Than 80% For At Least EIGHT MONTHS

Regeneron Pharmaceuticals Inc announced on Monday that its antibody cocktail can severely slash the risk of being infected with COVID-19 for up to eight months.

The combo therapy, REGEN-COV, was approved in November 2020 for emergency use to treat people with mild-to-moderate COVID-19 cases in the U.S.

But the U.S. Food and Drug Administration (FDA) expanded authorization in July 2021 so the drug can also be used as a preventive treatment.

Late-stage trial data showed a single dose can lower the risk of contracting Covid by 81.6 percent between two and six-months after the cocktail is administered.

The FDA has previously stated that REGEN-COV is not a replacement for vaccination, but rather can be used in conjunction with people who develop a weak immune response to the shots.